Thoratec REMATCH Preliminary Data Pumps Up Stock 43% In June
This article was originally published in The Gray Sheet
Executive Summary
Encouraging preliminary data from Thoratec's REMATCH trial for treatment of congestive heart failure with the HeartMate VE left ventricular assist system (LVAS) helped the firm's stock beat ahead 42.7% in June. The issue closed at $15.55 for the month, up $4.65.